company background image
BMXM.F logo

bioMérieux OTCPK:BMXM.F Stock Report

Last Price

US$102.39

Market Cap

US$12.1b

7D

-4.3%

1Y

-2.2%

Updated

20 Nov, 2024

Data

Company Financials +

BMXM.F Stock Overview

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details

BMXM.F fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends3/6

bioMérieux S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bioMérieux
Historical stock prices
Current Share Price€102.39
52 Week High€122.52
52 Week Low€93.50
Beta0.22
11 Month Change-10.30%
3 Month Change-4.54%
1 Year Change-2.24%
33 Year Change-23.87%
5 Year Change11.78%
Change since IPO175.98%

Recent News & Updates

Recent updates

Shareholder Returns

BMXM.FUS Medical EquipmentUS Market
7D-4.3%-0.4%-1.0%
1Y-2.2%20.3%30.3%

Return vs Industry: BMXM.F underperformed the US Medical Equipment industry which returned 20.9% over the past year.

Return vs Market: BMXM.F underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is BMXM.F's price volatile compared to industry and market?
BMXM.F volatility
BMXM.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: BMXM.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BMXM.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
196313,696Pierre Bouludwww.biomerieux.com

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
BMXM.F fundamental statistics
Market capUS$12.13b
Earnings (TTM)US$433.49m
Revenue (TTM)US$4.01b

28.0x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMXM.F income statement (TTM)
Revenue€3.81b
Cost of Revenue€1.69b
Gross Profit€2.12b
Other Expenses€1.71b
Earnings€411.30m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.49
Gross Margin55.72%
Net Profit Margin10.81%
Debt/Equity Ratio10.1%

How did BMXM.F perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

24%

Payout Ratio